Background and Purpose
Introduction
Oxidative stress resulting from the overproduction of reactive oxygen species (ROS), leads to endothelial dysfunction which is implicated in pathophysiology of several cardiovascular disorders (CVD) such as atherosclerosis, hypercholesterolemia, hypertension, Type 2 diabetes, and heart failure (Cai et al., 2000; Heitzer et al., 2001; Vita, 2011) . Excessive ROS generation within the vasculature may lead to the oxidation of low-density lipoproteins, decreased bio-availability of endothelium-derived nitric oxide (NO) (O'Donnell et al., 2001 ) and formation of peroxynitrite (ONOO ─ ), a highly reactive molecule (Beckman et al., 1996) . All these events are attributed to the impairment of the vascular endothelium function.
Endothelium -derived nitric oxide (NO) is an important signaling molecule which regulates the vessel homeostasis by inducing vascular smooth muscle relaxation, and inhibiting vascular smooth muscle hypertrophy, regulating platelet aggregation, and leukocyte adhesion (Gross et al., 1995) . In the endothelium, NO is produced by a family of enzymes termed nitric oxide synthases (NOSs) that catalyze the conversion of Larginine to L-citrulline and NO. The reactive oxygen and nitrogen species generated during oxidative stress are known to induce eNOS dysfunction that leads to the uncoupling of the enzyme and results in the production of NOS-derived O 2
•− instead of NO (Wei et al., 2003) . The resulting imbalance between NO and O 2 •− can contribute to the onset of a variety of cardiovascular diseases.
NOS activity is regulated by a complex cascade of phosphorylation/dephosphorylation at particular regulatory residues in the enzyme. Phosphorylation of eNOS S635 and S1179 leads to the activation of eNOS function while phosphorylation at threonine 497 downregulates it (Harris et al., 2001; Michell et al., 2001) . Activation by eNOS S1179 phosphorylation results from the enhanced electron flux through the reductase domain and inhibition of calmodulin-dissociation from the enzyme in a calcium-independent fashion (Fulton et al., 1999; McCabe et al., 2000) andis mediated by several upstream kinases, among which PI3/Akt has been reported to play a crucial role in the regulation of enzyme activity (Fulton et al., 1999) .
Most of the NO donor drugs are limited only by their NO delivering property and usually exhibit uncontrolled delivery of NO due to their instability in blood plasma (Wang et al., 2005) . Nitrones can both scavenge reactive species Villamena et al., 2004) and also exhibit controlled release of NO as a consequence (Locigno et al., 2005; Nash et al., 2012) , and is therefore, more desirable and unique among current drugs. To date, there are two major types of nitrones: the cyclic nitrones which include 5,5-dimethyl-1-pyrroline-N-oxide (DMPO), 5-carbamoyl-5-methyl-1-pyrroline-N-oxide (AMPO), 5-ethoxycarbonyl-5-methyl-1-pyrroline-N-oxide (EMPO), 5-(diethoxyphosphoryl)-5-methyl-1-pyrroline-N-oxide (DEPMPO), and the linear nitrones (PBN and NXY-059) α-phenyl-N-tert-butylnitrone (PBN), (disodium-[(tert-butylimino) methyl] benzene-1,3-disulfonate N-oxide (NXY-059) which have been used to detect free radicals. Nitrones though structurally simple molecules, yet they possess rich chemistries, and biological properties that make them important pharmacological agents Traynham et al., 2012; Villamena et al., 2012; Zamora et al., 2013; Zuo et al., 2009) . Nitrone spin traps such as DMPO, PBN and its derivative, NXY-059 have shown pharmacological activity against ischemia and reperfusion (I/R) injury in the heart and brain (Floyd, 2009; Zuo et al., 2009) , neurodegeneration (Floyd et al.) and cancer (Floyd, 2009; Floyd et al., 2008) . NXY-059 was the first neuroprotective agent that reached a clinical trial phase in the USA (Floyd et al., 2008) . Application of DMPO as a cardioprotective agent was previously reported (Tosaki et al., 1990) but its modes of action were unclear. DMPO also confered protection against cardiac IR injury in Langendorff rat heart preparations by salvaging the METC complexes and decreased ROS production (Zuo et al., 2009) . Other experimental evidences suggest involvement of other mechanisms for cardioprotection by DMPO other than its direct spin trapping properties such as induction of phase II enzymes via Nrf-2 nuclear translocation; and suppression of mitochondria-dependent pro-apoptotic signaling in endothelial cells .
Increase in mycoyte contraction via regulation of nitroso-redox levels and increase in sarcoplasmic reticulum Ca 2+ handling have also been proposed (Traynham et al., 2012) .
Although several works already described the reversal of eNOS uncoupling via supplementation with tetrahydrobiopterin (Forstermann, 2006) , in the present study, we explored the mechanism of reversal of eNOS dysfunction by post-treatment of endothelial cells with DMPO after treating the cells with the peroxynitrite donor, SIN-1, offering another mechanistic insights into the cardioprotective property of nitrones.
Methods

Cell culture and maintenance
BAEC were cultured using a T75 cm 2 flask in DMEM medium with 1g/L Dglucose and 4 mM L-glutamine, and supplemented with 10% fetal bovine serum, 50 µg/mL pencillin, 50 µg/mL streptomycin, 2.5 mg/L endothelial cell growth supplement, and 1% MEM-non essential amino acids at 37°C in a humidified atmosphere of 5% CO 2 and 20% O 2 . HEK293 (human embryonic kidney) were cultured under same conditions in DMEM media without endothelial cell growth supplement, and MEM-non essential amino acids. The medium was changed every 2-3 days and cells were sub-cultured once they reached 90-95% confluence or 80% for HEK293 cells.
SIN-1 and DMPO treatment of cells
BAEC or HEK293 were seeded at a density of 10 4 cells/mL in each well using a 24-well plate and grown to 70% confluency. Cells were treated with 500 µM SIN-1 for 2 h, and then post-incubated in plain medium without SIN-1 for additional 24 h, in the absence or presence of DMPO. For the cytoprotection studies, cells were treated with 500 µM SIN-1 for 2 h and subsequently post-incubated with DMPO for 24 h. Cell viability was assessed by MTT assay following the protocol described previously (Das et al., 2010) . Cell viability was calculated as the percentage of inhibition by the following formula (equation 1) :
where A t and A s are absorbance of the sample and solvent alone, respectively. Results were presented as mean ± SEM, where n = 6.
ROS detection by confocal microscopy
Cells with density of 10 4 cells/mL were seeded on sterile glass cover slips 6-well plate. Treated cells were fixed with 10% para-formaldehyde at room temperature for 10 min, washed with PBS three times and subsequently incubated with 25 μM of the fluorogenic probe DCFH-DA or 10 μM DHE for 30 min at 37°C, followed by nuclei staining with DAPI (1 µM) for 30 min. Images were then captured by Olympus FluoView-1000 confocal microscope using an excitation/emission filter of 543/602 nm for DHE, 488/535 nm for DCFH-DA and 405/422 nm for DAPI. Fluorescence intensities of 100 cells from different fields were calculated and results were presented as mean ± SEM of three independent experiments (n = 3).
ROS and NO detection by EPR spin trapping
Cells (10 4 cells/mL ) were grown to 70 % confluency in 6-well plates. After SIN-1 treatment, cells were incubated with 150 µl of EMPO (25 mM) and 150 µl of Me-β-CD (50 mM) and 10 µl of 10 μM CaI for 15 min (Šnyrychová, 2010) . The supernatant (300 µl) was transferred to a quartz flat cell and spin adduct formation was detected at room temperature using Bruker EMX X-Band EPR spectrometer. Experiment was repeated in the presence or absence of DMPO post-incubation. Instrument parameters were as follows: microwave frequency, 9.8 GHz; center field, 3485 G; modulation amplitude, 0.2-1.0 G; microwave power, 10 mW; conversion time: 41 ms; time constant: 82 ms, sweep time: 42 s; sweep width: 120 G; receiver gain, 1 x 10 5 and using incremental sweep. Spectra were simulated using an automatic fitting program (Rockenbauer et al., 1996) (Table S3 ). Spectra were obtained from three independent experiments (n = 3). Using the same cell cultures in 6-well plates, generation of NO in cells were detected by EPR spin trapping using Fe(MGD) 2 as the spin trap following the published protocol . Cells were washed with PBS after treatment, then incubated for 15 minutes with .
Determination of eNOS activity
eNOS activity was determined using the conversion of arginine to citrulline assay with [ 14 C]arginine as a substrate using the previously published protocol with a slight modification (Giraldez et al., 1998) . Cultured BAEC ( 
Measurement of BH 4 by HPLC chromatography
The total BH 4 was measured using HPLC analysis as described elsewhere (Dumitrescu et al., 2007; Hyland, 1985) . Cells were grown in T75 cm 2 flask up to 70%
confluency. SIN-1 treated cells were washed once with PBS and lysed with lysis buffer containing 1 mM ascorbate, 1 mM DTT and 100 μM DTPA, followed by sonication. The mixture was then centrifuged at 12000 x g for 1 min at 4 o C. The supernatant containing the protein was removed by filtration through a Microcom YM-3 spin column. The filtrates were injected to an ESA HPLC system with a C-18 column (T3 4.6 x 150 mm 5 micron) and HPLC separation was performed following the published protocol (Dumitrescu et al., 2007; Hyland, 1985) using mobile phase comprising of 50 mM potassium phosphate, 10 mM phosphate monobase, 12% ACN, 6 mM citric acid, 1 mM DTT, 5 mM octyl sulfate, pH 3 and isocratic elution at 1.2 mL/min. Detection parameters are: 35mV and 500mV for electrochemical cell; fluorescence: excitation at 348 nm and emission at 444 nm; UV at 254 nm. Results were presented as mean ± SEM of three independent experiments (n = 3).
Western blot analysis
Western blot analysis was performed to determine the expression levels of peNOS, p-Akt, t-Akt and t-eNOS proteins in untreated, SIN-1 treated, and nitrone-post incubated SIN-1 treated BAEC. Prior to treatment, cultured BAEC (10 4 cells/ mL) were grown to 70 % confluency on 60 mm petri-dishes, and 50 µg of protein from each set was used for western blotting. In a separate experimental set, the membrane was incubated with mouse monoclonal anti-p-eNOS (S1179) antibody (1:1000 dilution), mouse monoclonal anti p-Akt (Ser-473) antibody (1:500 dilution), mouse monoclonal anti-teNOS antibody (1:1000 dilution), mouse monoclonal anti-t-Akt antibody (1:500 dilution) and mouse monoclonal anti-β-actin antibody (1:1000 dilution) overnight at 4 o C. The protein bands were visualized using chemiluminiscence kit available commercially and the bands were quantified densitometrically using available software.
Transient transfection of HEK293 cells with wild type and mutant eNOS cDNAs
Human embryonic kidney cells were transfected with 5 µg/µl of eNOS cDNA (wild type and mutant where S1179 was changed to alanine) (Lin et al., 2003) using Lipofectamine TM 2000 (Invitrogen) as per manufacturer's instruction. The transfection efficiency was analyzed using western blot analysis of eNOS proteins and by measuring NO levels.
Statistical analysis
Data are presented as the mean of at least three independent experiments along with standard error of the mean (SEM). Statistical analysis of data was done by one-way analysis of variance (ANOVA), with Student-Newman-Keul test by using Sigma plot 12.0. The p value <0.05 was considered to be statistically significant.
Results
Dose-and time-dependent cytoprotective effects from post-treatment by DMPO of SIN-
1-challenged BAEC
Treatment of cells with varying concentrations of DMPO alone (25-500 µM) for 24 h did not result in loss of cell viability ( Figure S1 ). However, cells challenged with 500 µM SIN-1 at varying time periods resulted in significant cytotoxicity ( Figure S2 ). A 50% decrease in cell viability was observed after 2 h of SIN-1 treatment followed by 24 h of post-incubation in plain media (without SIN-1) ( Figure S2 ). SIN-1 has been suggested to induce cell death via two mechanisms, production of peroxynitrite (ONOO ─ ) through reaction between NO and O 2 •− to finally form HO • (Ishii et al., 1999) , and generation of H 2 O 2 (Lomonosova et al., 1998) . (Table S2 and Figures 2C-2D .
Restoration of NO bioavailability in SIN-1-treated BAEC by DMPO
Since oxidative stress leads to decreased bioavailability of NO (Cai et al., 2000) , the effect of SIN-1 on NO production in BAEC was investigated. Using EPR and Fe(MGD) 2 as spin trap to detect NO generation ( Figures 3A and 3B ), a significant decrease in NO production of almost 50% was observed when cells were treated with SIN-1 for 2 h and post-incubated in plain media for 24 h. The same observation was previously reported for BAEC upon treatment with SIN-1 or ONOO ─ (Kuzkaya et al., 2003) . However, post-treatment with DMPO for 24 h resulted in the restoration of the NO levels by about 35%. Treatment of cells with the NOS inhibitor L-NAME, completely abolished the NO-signal ( Figure 3B ) indicating an eNOS-derived NO production.
Restoration of eNOS activity in SIN-1-treated BAEC by DMPO
eNOS activity was assessed using the L-[ 14 C] arginine to L-[ 14 C] citrulline conversion assay. BAEC were treated with SIN-1 for 2 h and post-incubated for another 24 h that resulted in significant inhibition of eNOS activity by ~30%. However, posttreatment with DMPO for 24 h led to the complete restoration of eNOS activity ( Figure   3C ). This provides definitive evidence that the effects of DMPO on NO production are mediated at least in part through increased eNOS-derived NO production and not merely a consequence of scavenging SIN-1-derived superoxide.
Increased bioavailability of NO in BAEC treated with DMPO alone
Since post-treatment with DMPO resulted in a significant increase in NO production and NOS activity in SIN-challenged cells, we investigated if the nitrone alone could increase NO generation in BAEC without oxidatively challenging the cells. EPR studies revealed that treatment of cells with DMPO resulted in a time-dependent increase in cellular NO and a 40% increase in NO production was observed after 24 h of treatment (Figure 4 ).
Determination of NO source: nitrone versus L-Arginine
To determine if the source of the generated NO is through nitrone-decomposition (Locigno et al., 2005) demonstrating that most of the detected NO were generated from the 15 N-labeled arginine ( Figure 5B ). This result suggests that the NO generated in BAEC upon DMPO-treatment did not originate from the nitrone itself, but rather from the metabolism of L-arginine to L-citrulline, and thus, implicates NOS as the source of the NO.
Induction of eNOS-and Akt-phosphorylation in BAEC by DMPO in the absence of
SIN-1 treatment
Western blot was performed to detect p-eNOS S1179 in BAEC treated with DMPO for 12 h and 24 h. A time-dependent increase in p-eNOS levels was observed due to DMPO treatment with a significant 2.2-fold increase after 12 h of incubation. The peNOS level was found to be slightly increased after 24 h of treatment ( Figures 6A and   6B ). Since protein kinase B or Akt is known to be an upstream regulator of eNOS and results in the phosphorylation of the enzyme (Fulton et al., 1999) were post-treated with DMPO for 24 h, p-eNOS levels were significantly restored ( Figures 7C and 7D ). In addition, we also observed significant restoration of p-Akt levels in SIN-1-treated BAEC upon post-treatment with DMPO ( Figures 7C and 7E ). These observations show that DMPO can increase NO-bioavailability in SIN-1-challenged BAEC via phosphorylation of Akt and eNOS.
SIN-1 mediated eNOS dysfunction is independent of BH 4 depletion
Treatment of BAEC with SIN-1 for 2 h in the absence of DMPO resulted in the depletion of BH 4 -levels but upon incubation in plain media for additional 24 h, BH 4 -levels were restored in SIN-1 challenged cells ( Figure S6 ). This indicates that BH 4 is metabolically replenished after 24 h of incubation, and therefore, is independent of DMPO action. We also investigated the effect of DMPO on BH 4 state within an hour of SIN-1 administration to the cell but showed no significant change in the BH 4 levels similar to in the absence of DMPO.
Dual roles of eNOS as target for both SIN-1 and DMPO
HEK293 cells were transfected with the cDNAs encoding both wild type and mutant (S1179A) bovine eNOS. This mutant eNOS was reported to be resistant to phosphorylation and also did not exhibit any Akt-dependent increase in NO-generation (Fulton et al., 1999) . Western blot results show equal transfection efficiency for both wild type and mutant eNOS ( Figure S7B ) but no NO generation from mutant eNOS and with NO generation in wild-type eNOS-transfected cells were observed ( Figure S7A ). When Figure 8D ) confirming the role of eNOS S1179 in radical generation.
It has been shown that phosphorylation of eNOS S1177 at low Ca 2+ concentrations is critical for O 2 •− generation (Chen et al., 2008) .
To investigate whether DMPO can attenuate SIN-1 mediated ROS generation in HEK293 cells transfected with wild type or mutant eNOS-plasmid, confocal microscopy using DCF-DA stain was employed to detect ROS generation and revealed that SINtreatment gave a ~4.4-fold increase in DCF-fluorescence intensity and is significantly reduced on post-treatment with DMPO ( Figure S8A-8B ).
Discussion
Oxidative insult to eNOS can reverse its function from being an NO generator to a pro-oxidative enzyme, thereby exacerbating the degenerative processes that have been associated with endothelial dysfunction (Cai et al., 2000) . In this work, we demonstrated how DMPO can reverse eNOS function from being pro-oxidative to that of its normal NO synthase function by exploiting the nitrone's ability to regulate the nitroso-redox balance in the cell by scavenging ROS, increasing NO bioavailability, and ultimately eNOS phosphorylation.
Post-treatment by DMPO of SIN-1-challenged BAEC conferred cytoprotection and restored NO production, while post-incubation of BAEC with SIN-1 for an additional 24 h in plain medium (in the absence of DMPO) gradually increased the oxidative burden on the cells. Production of ONOO ─ via formation of ROS and NO had been implicated in SIN-1 cytotoxicity to endothelial cells (Ishii et al., 1999) . Although nitrones are known to react with ONOO ─ , where ONOO ─ /ONOOH mediates the formation of the spin adducts using DMPO as spin trap (Gatti et al., 1998; Nash et al., 2012) , the possibility that DMPO may be converting SIN-1 as an NO donor rather than a ONOO -via O 2
•− scavenging is unlikely since two hours of SIN-1 incubation with cells would not allow ONOO -to persist due to its short half-life (1.9 sec at pH 7.4) (Beckman et al., 1990) especially in the presence of biological milieu. Furthermore, fluorescence studies showed that the half-time for the steady state ONOO -production from SIN-1 range from 14 min to 26 min (Martin-Romero et al., 2004) . One could envision that after 2 hour incubation of cells with SIN-1, ONOO -is released into the cell and could have had reacted already causing oxidative damage perhaps to eNOS. Therefore, the observed ROS adducts formation during spin trapping is not a direct reaction of ONOO -with DMPO. These results clearly suggest that post-treatment of cells with DMPO attenuates ROS production in SIN-1-treated endothelial cells via eNOS dysfunction.
ROS-derived ONOO ─ limits bioavailability of the eNOS cofactor, BH 4 , resulting from either BH 4 -depletion or oxidation thereby resulting to eNOS dysfunction (Kuzkaya et al., 2003) . Previous studies also showed that in BAEC, co-incubation of BH 4 or ascorbic acid with SIN-1 can reverse the effect of SIN-1 on NO production perhaps via replenishment of oxidized BH 4 or reversal in the oxidation state of the redox-modified BH 4 (Kuzkaya et al., 2003; Vasquez-Vivar et al., 2002; Xia et al., 1998) . However, unlike ascorbic acid (Kuzkaya et al., 2003) , DMPO does not reverse eNOS function through restoration of BH 4 levels during initial and 24 hours of SIN-1 treatments, and that the observed reduced NO and increase ROS productions could be a result of other mechanisms other than uncoupling due to BH 4 oxidation.
Therefore, the role of eNOS activation via phosphorylation was investigated to explain the observed increase in NO production in DMPO-treated cells. Phosphorylation of eNOS S1179 is known to activate eNOS by stimulating the flux of electrons within the reductase domain (Harris et al., 2001; McCabe et al., 2000; Michell et al., 2001) . Under oxidative stress conditions, eNOS generates O 2 •− and phosphorylation of eNOS S1179 is inhibited leading to decrease in NO production. How phosphorylation of eNOS S1179 is regulated to maintain the O 2
•− -NO balance under oxidative stress conditions is not completely understood (Xia et al., 1996) but it has been proposed that eNOS phosphorylation is redox-sensitive and is activated by PI3K/Akt pathway (Dimmeler et al., 1999; Fulton et al., 1999) and by other kinases (Alhosin et al., 2013) . Regulation of ATP levels and activation of other kinases such as p38 MAPK and JNK by DMPO, therefore, warrants further investigation. This study, nevertheless, demonstrates that DMPO can reverse eNOS dysfunction through decreased ROS production, increased in NO bioavailability and increased phosphorylation of eNOS S1179 Akt activation.
Traditional antioxidants such as ascobic acid and N-acetyl cysteine have been explored for their ability to prevent or reverse eNOS uncoupling in BAEC (Kuzkaya et al., 2003) and in diabetic rat hearts (Okazaki et al., 2011) through an increase in the BH 4 /BH 2 ratio. Recently, lipophilic NO-donor and lipophilic antioxidants, when introduced as a hybrid molecule and not as a mixture, can exhibit cardiac protection from I/R through significant reduction of infarct size with improved recovery of cardiac function (Rastaldo et al., 2012) , however, the mechanism of this protection was not clear.
Moreover, magnesium lithospermate B have been shown to protect endothelium from hyperglycemia-induced dysfunction via eNOS phosphorylation, and induction of phase II enzymes by Nrf-2 nuclear translocation, while α-lipoic acid was claimed to be not able to cause these effects (Traynham et al., 2012) .
Cardiometabolic disease is a growing health problem that is a combination of various risk factors such as hypertension, hyperglycemia and elevated plasma triglyceride levels, leading to the development of Type 2 diabetes and cardiovascular diseases. While the antioxidants mentioned above could be promising, their therapeutic application could be limited in the treatment of cardiometabolic diseases since unlike nitrones, their modes of action may only be limited to few mechanisms (Zamora et al., 2013) . Findings presented in this present work and in our past studies Durand et al., 2009; Traynham et al., 2012; Zuo et al., 2009) showed that nitrones offer opportunities for the application of nitrones in the treatment of cardiometabolic disorders such as hypertension and hyperglycemia which are associated with endothelial dysfunction and depletion of cellular antioxidant pool since nitrones do not only scavenge ROS (Durand et al., 2008; Durand et al., 2009 ) but also acts through NO donation (Locigno et al., 2005) ; salvaging METC activity (Zuo et al., 2009) ; increase METC biogenesis (Zuo et al., 2009) ; inhibition of mitochondrial polarization leading to down regulation of proapoptotic signaling pathways; induction of phase II enzyme activities via NRF-2 nuclear translocation ; increased myocyte contraction via increased sarcoplasmic reticulum Ca 2+ handling (Traynham et al., 2012) and in this study, reversal of eNOS dysfunction.
Future work needs to investigate how DMPO activates Akt by immuno-spin trapping of the relevant proteins and role of nitrones as a potential phosphatase inhibitor, since protein phosphatase 2A (PP2A) was also reported to decrease eNOS S1179 phosphorylation. Therefore, therapeutic agents that can target cytosolic matrix and affect kinase mediated phosphorylation processes in the cell may be able to up-regulate eNOS. Attempts had been made to conjugate cyclic nitrones to several target specific groups in order to facilitate their delivery to specific subcellular compartments (Durand et al., 2010; Durand et al., 2003; Durand et al., 2009) since the poor target specificity of some of the natural antioxidants such as vitamin E, vitamin C, or lipoic acid are limiting their applications against ROS-induced CVDs (Kizhakekuttu et al., 2010; Shay et al., 2009; Willcox et al., 2008) . Considering that eNOS is mostly localized near the cell membrane and that mitochondria and sarcoplasmic reticulum are mostly cytosolic, the use of nitrones that can specifically target these compartments can provide opportunities to identifying which targeted cellular event/s contributes the greatest to I/R injury and which target-specific nitrone will exhibit the most robust protection can give valuable insights into the mechanisms of nitrone protection. To date, targeting oxidative stress at the site/s of their origination still remains an attractive strategy for cardiovascular prevention and therapy (Munzel et al., 2010) . Therefore, deeper understanding of radical sources and mechanisms of oxidative stress, and the development of more target specific antioxidants with multi-functional action such as those exhibited by nitrones are necessary. Table S2 
